← Back to search
7prv

The glucocorticoid receptor in complex with fluticasone furoate, a PGC1a coactivator fragment and sgk 23bp

Method: X-RAY DIFFRACTION Dmax: 94.2 Å Quality: EXCELLENT
▼

1. Protein Identity and Related Structures Protein Identity & Related Structures

Glucocorticoid receptor

Homo sapiens

UniProt P04150

State in the Current Structure

Assembly Oligomeric State Construct Mutations and Modifications Ligands, Ions and Associated Components Method and Experimental Conditions Structure Quality
1 Protein–DNA Heteromer Protein × 3 DNA 2 PDB declaration: pentameric（5） Consistent with all polymer counts Chain A； UniProt 385–777 Chain B； UniProt 385–777 Mutation：S404A, N517D, V571M, F602S, C638D ;DNA (5'-D(*TP*CP*GP*AP*CP*GP*GP*AP*CP*AP*AP*AP*AP*TP*GP*TP*TP*CP*TP*GP*TP*A)-3') ; × 1 ;DNA (5'-D(*TP*AP*CP*AP*GP*AP*AP*CP*AP*TP*TP*TP*TP*GP*TP*CP*CP*GP*TP*CP*GP*A)-3') ; × 1 Peroxisome proliferator-activated receptor gamma coactivator 1-alpha × 1 （Q9UBK2） ZN ZINC ION × 4 EDO 1,2-ETHANEDIOL × 3 GW6 (6alpha,11alpha,14beta,16alpha,17alpha)-6,9-difluoro-17-{[(fluoromethyl)sulfanyl]carbonyl}-11-hydroxy-16-methyl-3-oxoan drosta-1,4-dien-17-yl furan-2-carboxylate × 2 X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；8 % PEG3350, 0.3 M 1,6-hexanediol, 0.1 M guanidine hydrochloride, 8 % 2,2,2-trifluoroethanol, 0.1 M Bis Tris Propane pH 6.5 Resolution 2.70 Å R-free 0.253

Other States of the Same Protein in the Database

Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.

Other PDB Difference from Current Entry 7PRV Assembly / Oligomeric State Construct Mutations and Modifications Ligands, Ions and Non-polymers Method and Experimental Conditions Structure Quality
1M2Z Crystal structure of a dimer complex of the human glucocorticoid receptor ligand-binding domain bound to dexamethasone and a TIF2 coactivator motif Deposited 2002-06-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain A 521–777（257 aa） Fragment：Ligand Binding Domain, residues 521-777
Chain D 521–777（257 aa） Fragment：Ligand Binding Domain, residues 521-777
Mutation：F602S Mutation：F602S BOG octyl beta-D-glucopyranoside × 3 DEX DEXAMETHASONE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；293 K；salts, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.50 Å R-free 0.267
1NHZ Crystal Structure of the Antagonist Form of Glucocorticoid Receptor Deposited 2002-12-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 500–777（278 aa） Fragment：residue 500-777, hinge and steroid binding domains
Mutation：N517D, F602S, C638D 486 11-(4-DIMETHYLAMINO-PHENYL)-17-HYDROXY-13-METHYL-17-PROP-1-YNYL-1,2,6,7,8,11,12,13,14,15,16,17-DODEC AHYDRO-CYCLOPENTA[A]PHENANTHREN-3-ONE × 1 HEZ HEXANE-1,6-DIOL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.2；288 K；PEG 8000, 1, 6-hexanediol, NaSCN, Tris-HCl, pH 8.2, VAPOR DIFFUSION, HANGING DROP, temperature 288K
Resolution 2.30 Å R-free 0.276
1NHZ Crystal Structure of the Antagonist Form of Glucocorticoid Receptor Deposited 2002-12-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 500–777（278 aa） Fragment：residue 500-777, hinge and steroid binding domains
Mutation：N517D, F602S, C638D 486 11-(4-DIMETHYLAMINO-PHENYL)-17-HYDROXY-13-METHYL-17-PROP-1-YNYL-1,2,6,7,8,11,12,13,14,15,16,17-DODEC AHYDRO-CYCLOPENTA[A]PHENANTHREN-3-ONE × 2 HEZ HEXANE-1,6-DIOL × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.2；288 K；PEG 8000, 1, 6-hexanediol, NaSCN, Tris-HCl, pH 8.2, VAPOR DIFFUSION, HANGING DROP, temperature 288K
Resolution 2.30 Å R-free 0.276
1P93 CRYSTAL STRUCTURE OF THE AGONIST FORM OF GLUCOCORTICOID RECEPTOR Deposited 2003-05-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 500–777（278 aa） Fragment：RESIDUE 500-777, hinge and steroid binding domains
Mutation：N517D, F602S, C638D DEX DEXAMETHASONE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；281 K；PEG 400, MgCl2, Dioxane, Tris, pH 8.5, VAPOR DIFFUSION, HANGING DROP
Resolution 2.70 Å R-free 0.363
1P93 CRYSTAL STRUCTURE OF THE AGONIST FORM OF GLUCOCORTICOID RECEPTOR Deposited 2003-05-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 500–777（278 aa） Fragment：RESIDUE 500-777, hinge and steroid binding domains
Mutation：N517D, F602S, C638D DEX DEXAMETHASONE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；281 K；PEG 400, MgCl2, Dioxane, Tris, pH 8.5, VAPOR DIFFUSION, HANGING DROP
Resolution 2.70 Å R-free 0.363
1P93 CRYSTAL STRUCTURE OF THE AGONIST FORM OF GLUCOCORTICOID RECEPTOR Deposited 2003-05-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 500–777（278 aa） Fragment：RESIDUE 500-777, hinge and steroid binding domains
Mutation：N517D, F602S, C638D DEX DEXAMETHASONE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；281 K；PEG 400, MgCl2, Dioxane, Tris, pH 8.5, VAPOR DIFFUSION, HANGING DROP
Resolution 2.70 Å R-free 0.363
1P93 CRYSTAL STRUCTURE OF THE AGONIST FORM OF GLUCOCORTICOID RECEPTOR Deposited 2003-05-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 4 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 500–777（278 aa） Fragment：RESIDUE 500-777, hinge and steroid binding domains
Mutation：N517D, F602S, C638D DEX DEXAMETHASONE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；281 K；PEG 400, MgCl2, Dioxane, Tris, pH 8.5, VAPOR DIFFUSION, HANGING DROP
Resolution 2.70 Å R-free 0.363
3BQD Doubling the Size of the Glucocorticoid Receptor Ligand Binding Pocket by Deacylcortivazol Deposited 2007-12-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 525–777（253 aa） Fragment：glucocorticoid receptor ligand binding domain (residues 525-777)
Mutation：F602S DAY 1-[(1R,2R,3aS,3bS,10aR,10bS,11S,12aS)-1,11-dihydroxy-2,5,10a,12a-tetramethyl-7-phenyl-1,2,3,3a,3b,7,10,10a,10b,11,12,12a-dodecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-yl]-2-hydroxyethanone × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；298 K；1.3 M ammonium sulfate, 100 mM Tris, 8% glycerol, 3 mM n-hexadecyl-beta-maltoside, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
Resolution 2.50 Å R-free 0.261
3CLD Ligand binding domain of the glucocorticoid receptor complexed with fluticazone furoate Deposited 2008-03-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain A 521–777（257 aa） Fragment：ligand binding domain, UNP residues 521-777
Chain B 521–777（257 aa） Fragment：ligand binding domain, UNP residues 521-777
Mutation：F602Y, C638G Mutation：F602Y, C638G GW6 (6alpha,11alpha,14beta,16alpha,17alpha)-6,9-difluoro-17-{[(fluoromethyl)sulfanyl]carbonyl}-11-hydroxy-16-methyl-3-oxoan drosta-1,4-dien-17-yl furan-2-carboxylate × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；295 K；100mM BisTrisPropane, 2.2M NaCl, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 2.84 Å R-free 0.267
3E7C Glucocorticoid Receptor LBD bound to GSK866 Deposited 2008-08-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain A 521–777（257 aa） Fragment：UNP RESIDUES 521-777
Chain B 521–777（257 aa） Fragment：UNP RESIDUES 521-777
Mutation：F602Y, C638G Mutation：F602Y, C638G 866 5-amino-N-[(2S)-2-({[(2,6-dichlorophenyl)carbonyl](ethyl)amino}methyl)-3,3,3-trifluoro-2-hydroxypropyl]-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide × 2 GOL GLYCEROL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；0.1M MES pH 6.5, 1.6M MgSO4, 0.1% betahexaglucoside, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 2.15 Å R-free 0.266
3E7C Glucocorticoid Receptor LBD bound to GSK866 Deposited 2008-08-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 521–777（257 aa） Fragment：UNP RESIDUES 521-777
Mutation：F602Y, C638G 866 5-amino-N-[(2S)-2-({[(2,6-dichlorophenyl)carbonyl](ethyl)amino}methyl)-3,3,3-trifluoro-2-hydroxypropyl]-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；0.1M MES pH 6.5, 1.6M MgSO4, 0.1% betahexaglucoside, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 2.15 Å R-free 0.266
3E7C Glucocorticoid Receptor LBD bound to GSK866 Deposited 2008-08-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 521–777（257 aa） Fragment：UNP RESIDUES 521-777
Mutation：F602Y, C638G 866 5-amino-N-[(2S)-2-({[(2,6-dichlorophenyl)carbonyl](ethyl)amino}methyl)-3,3,3-trifluoro-2-hydroxypropyl]-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide × 1 GOL GLYCEROL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；0.1M MES pH 6.5, 1.6M MgSO4, 0.1% betahexaglucoside, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 2.15 Å R-free 0.266
3H52 Crystal structure of the antagonist form of human glucocorticoid receptor Deposited 2009-04-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric
Chain A 528–777（250 aa） Fragment：Steroid-binding domain, UNP residues 528-777
Chain D 528–777（250 aa） Fragment：Steroid-binding domain, UNP residues 528-777
Mutation：F602S,C638D,W712S, E684A, E688A Mutation：F602S,C638D,W712S, E684A, E688A 486 11-(4-DIMETHYLAMINO-PHENYL)-17-HYDROXY-13-METHYL-17-PROP-1-YNYL-1,2,6,7,8,11,12,13,14,15,16,17-DODEC AHYDRO-CYCLOPENTA[A]PHENANTHREN-3-ONE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；VAPOR DIFFUSION, SITTING DROP
Resolution 2.80 Å R-free 0.283
3H52 Crystal structure of the antagonist form of human glucocorticoid receptor Deposited 2009-04-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric
Chain B 528–777（250 aa） Fragment：Steroid-binding domain, UNP residues 528-777
Chain C 528–777（250 aa） Fragment：Steroid-binding domain, UNP residues 528-777
Mutation：F602S,C638D,W712S, E684A, E688A Mutation：F602S,C638D,W712S, E684A, E688A 486 11-(4-DIMETHYLAMINO-PHENYL)-17-HYDROXY-13-METHYL-17-PROP-1-YNYL-1,2,6,7,8,11,12,13,14,15,16,17-DODEC AHYDRO-CYCLOPENTA[A]PHENANTHREN-3-ONE × 2 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；VAPOR DIFFUSION, SITTING DROP
Resolution 2.80 Å R-free 0.283
3K22 Glucocorticoid Receptor with Bound alaninamide 10 with TIF2 peptide Deposited 2009-09-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 521–777（257 aa）
Mutation：F602Y, C638G JZS N-[(1R)-2-amino-1-methyl-2-oxoethyl]-3-(6-methyl-4-{[3,3,3-trifluoro-2-hydroxy-2-(trifluoromethyl)propyl]amino}-1H-indazol-1-yl)benzamide × 1 JZR hexyl beta-D-glucopyranoside × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.10 Å R-free 0.255
3K22 Glucocorticoid Receptor with Bound alaninamide 10 with TIF2 peptide Deposited 2009-09-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 521–777（257 aa）
Mutation：F602Y, C638G JZS N-[(1R)-2-amino-1-methyl-2-oxoethyl]-3-(6-methyl-4-{[3,3,3-trifluoro-2-hydroxy-2-(trifluoromethyl)propyl]amino}-1H-indazol-1-yl)benzamide × 1 JZR hexyl beta-D-glucopyranoside × 2 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.10 Å R-free 0.255
3K23 Glucocorticoid Receptor with Bound D-prolinamide 11 Deposited 2009-09-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 521–777（257 aa） Fragment：UNP residues 521-777, Ligand Binding Domain
Mutation：F602Y, C638G JZN 1-{[3-(4-{[(2R)-4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl]amino}-6-methyl-1H-indazol-1-yl)phenyl]carbonyl}-D-prolinamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；0.1M MES 6.5, 28% PEG 5K MME, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 3.00 Å R-free 0.289
3K23 Glucocorticoid Receptor with Bound D-prolinamide 11 Deposited 2009-09-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 521–777（257 aa） Fragment：UNP residues 521-777, Ligand Binding Domain
Mutation：F602Y, C638G JZN 1-{[3-(4-{[(2R)-4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl]amino}-6-methyl-1H-indazol-1-yl)phenyl]carbonyl}-D-prolinamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；0.1M MES 6.5, 28% PEG 5K MME, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 3.00 Å R-free 0.289
3K23 Glucocorticoid Receptor with Bound D-prolinamide 11 Deposited 2009-09-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 521–777（257 aa） Fragment：UNP residues 521-777, Ligand Binding Domain
Mutation：F602Y, C638G JZN 1-{[3-(4-{[(2R)-4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl]amino}-6-methyl-1H-indazol-1-yl)phenyl]carbonyl}-D-prolinamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；0.1M MES 6.5, 28% PEG 5K MME, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 3.00 Å R-free 0.289
4CSJ The discovery of potent selective glucocorticoid receptor modulators, suitable for inhalation Deposited 2014-03-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 500–777（278 aa） Fragment：LIGAND BINDING DOMAIN, RESIDUES 500-777
Mutation：YES EDO 1,2-ETHANEDIOL × 1 NN7 N-[(2S)-1-[[1-(4-fluorophenyl)indazol-4-yl]amino]propan-2-yl]-2,4,6-trimethyl-benzenesulfonamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；10% PEG8000, 20% ETHYLENE GLYCOL AND 0.1 M HEPES PH7.5
Resolution 2.30 Å R-free 0.234
4HN5 GR DNA Binding Domain - TSLP nGRE Complex Deposited 2012-10-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric
Chain A 417–506（90 aa） Fragment：Glucocorticoid Receptor DNA Binding Domain
Chain B 417–506（90 aa） Fragment：Glucocorticoid Receptor DNA Binding Domain
Not recorded ZN ZINC ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；15 % PEG 20000, 6 % glycerol, 7.5 % ethanol, 0.1M HEPES pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 1.90 Å R-free 0.235
4HN6 GR DNA Binding Domain R460D/D462R - TSLP nGRE Complex Deposited 2012-10-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric
Chain A 417–506（90 aa）
Chain B 417–506（90 aa）
Mutation：R460D,D462R Mutation：R460D,D462R ZN ZINC ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；15 % PEG 2000 MME, 6 % glycerol, 0.1M HEPES pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.55 Å R-free 0.248
4LSJ Crystal Structure of the Glucocorticoid Receptor Ligand Binding Domain Bound to a Dibenzoxapine Sulfonamide Deposited 2013-07-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain A 522–777（256 aa） Fragment：Steroid-binding region, residues 522-777
Mutation：F602Y, C638G LSJ N-{3-[(1Z)-1-(10-methoxydibenzo[b,e]oxepin-11(6H)-ylidene)propyl]phenyl}methanesulfonamide × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；294.15 K；0.1 M bis-tris propane pH 5.5, 0.3 M Magnesium Formate, VAPOR DIFFUSION, SITTING DROP, temperature 294.15K
Resolution 2.35 Å R-free 0.236
4LSJ Crystal Structure of the Glucocorticoid Receptor Ligand Binding Domain Bound to a Dibenzoxapine Sulfonamide Deposited 2013-07-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 522–777（256 aa） Fragment：Steroid-binding region, residues 522-777
Mutation：F602Y, C638G LSJ N-{3-[(1Z)-1-(10-methoxydibenzo[b,e]oxepin-11(6H)-ylidene)propyl]phenyl}methanesulfonamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；294.15 K；0.1 M bis-tris propane pH 5.5, 0.3 M Magnesium Formate, VAPOR DIFFUSION, SITTING DROP, temperature 294.15K
Resolution 2.35 Å R-free 0.236
4MDD Crystal Structure of the Glucocorticoid Receptor Bound to a Non-steroidal Antagonist Reveals Repositioning and Partial Disordering of Activation Function Helix 12 Deposited 2013-08-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain A 522–777（256 aa） Fragment：unp residues 522-777
Chain B 522–777（256 aa） Fragment：unp residues 522-777
Mutation：L525S, L528S, L535A, V538T, F602Y, C638D, E684A, E688A, W712S Mutation：L525S, L528S, L535A, V538T, F602Y, C638D, E684A, E688A, W712S 29M N-[2-{[benzyl(methyl)amino]methyl}-3-(4-fluoro-2-methoxyphenyl)-5-(propan-2-yl)-1H-indol-7-yl]methanesulfonamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；294 K；100mM Tris HCl plus 6% 1,6 - Hexanediol + 24% PEG 8K, pH 7, VAPOR DIFFUSION, SITTING DROP, temperature 294K
Resolution 2.40 Å R-free 0.258
4P6W Crystal Structure of mometasone furoate-bound glucocorticoid receptor ligand binding domain Deposited 2014-03-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 526–777（252 aa） Fragment：Ligand binding domain (UNP residues 526-777)
Mutation：F602A, C622Y, T668V, S674T, V675I, K699A, K703A MOF MOMETASONE FUROATE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；0.1 M imidazole, pH6.5, and 1 M sodium acetate trihydrate. 30% sucrose
Resolution 1.95 Å R-free 0.225
4P6X Crystal Structure of cortisol-bound glucocorticoid receptor ligand binding domain Deposited 2014-03-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 523–777（255 aa） Fragment：Ligand binding domain (UNP residues 523-777)
Mutation：F602A, C622Y, T668V, S674T, V675I, E684A, E688A HCY (11alpha,14beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；0.1 M imidazole, pH6.5, and 1 M sodium acetate trihydrate. 30% sucrose
Resolution 2.50 Å R-free 0.276
4P6X Crystal Structure of cortisol-bound glucocorticoid receptor ligand binding domain Deposited 2014-03-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 523–777（255 aa） Fragment：Ligand binding domain (UNP residues 523-777)
Mutation：F602A, C622Y, T668V, S674T, V675I, E684A, E688A HCY (11alpha,14beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；0.1 M imidazole, pH6.5, and 1 M sodium acetate trihydrate. 30% sucrose
Resolution 2.50 Å R-free 0.276
4P6X Crystal Structure of cortisol-bound glucocorticoid receptor ligand binding domain Deposited 2014-03-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain E 523–777（255 aa） Fragment：Ligand binding domain (UNP residues 523-777)
Mutation：F602A, C622Y, T668V, S674T, V675I, E684A, E688A HCY (11alpha,14beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；0.1 M imidazole, pH6.5, and 1 M sodium acetate trihydrate. 30% sucrose
Resolution 2.50 Å R-free 0.276
4P6X Crystal Structure of cortisol-bound glucocorticoid receptor ligand binding domain Deposited 2014-03-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 4 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain G 523–777（255 aa） Fragment：Ligand binding domain (UNP residues 523-777)
Mutation：F602A, C622Y, T668V, S674T, V675I, E684A, E688A HCY (11alpha,14beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；0.1 M imidazole, pH6.5, and 1 M sodium acetate trihydrate. 30% sucrose
Resolution 2.50 Å R-free 0.276
4P6X Crystal Structure of cortisol-bound glucocorticoid receptor ligand binding domain Deposited 2014-03-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 5 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain I 523–777（255 aa） Fragment：Ligand binding domain (UNP residues 523-777)
Mutation：F602A, C622Y, T668V, S674T, V675I, E684A, E688A HCY (11alpha,14beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；0.1 M imidazole, pH6.5, and 1 M sodium acetate trihydrate. 30% sucrose
Resolution 2.50 Å R-free 0.276
4P6X Crystal Structure of cortisol-bound glucocorticoid receptor ligand binding domain Deposited 2014-03-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 6 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain K 523–777（255 aa） Fragment：Ligand binding domain (UNP residues 523-777)
Mutation：F602A, C622Y, T668V, S674T, V675I, E684A, E688A HCY (11alpha,14beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；0.1 M imidazole, pH6.5, and 1 M sodium acetate trihydrate. 30% sucrose
Resolution 2.50 Å R-free 0.276
4UDC GR in complex with dexamethasone Deposited 2014-12-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 500–777（278 aa） Fragment：LIGAND BINDING DOMAIN, UNP RESIDUES 500-777
Mutation：YES CPS 3-[(3-CHOLAMIDOPROPYL)DIMETHYLAMMONIO]-1-PROPANESULFONATE × 1 DEX DEXAMETHASONE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；10% PEG8000, 10% ETHYLENE GLYCOL, 0.1 M HEPES PH 7.5
Resolution 2.50 Å R-free 0.253
4UDD GR in complex with desisobutyrylciclesonide Deposited 2014-12-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 500–777（278 aa） Fragment：LIGAND BINDING DOMAIN, UNP RESIDUES 500-777
Mutation：YES CPS 3-[(3-CHOLAMIDOPROPYL)DIMETHYLAMMONIO]-1-PROPANESULFONATE × 3 EDO 1,2-ETHANEDIOL × 1 CV7 DESISOBUYTYRYL CICLESONIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；10% PEG8000, 20% ETHYLENE GLYCOL, 0.1 M HEPES PH 7.5
Resolution 1.80 Å R-free 0.224
5CC1 S425G Glucocorticoid receptor DNA binding domain - (+)GRE complex Deposited 2015-07-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric
Chain A 391–480（90 aa）
Chain B 391–480（90 aa）
Mutation：S425G Mutation：S425G ZN ZINC ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；0.1 M HEPES, 20% PEG 8000, and 4% ethylene glycol
Resolution 2.30 Å R-free 0.279
5CC1 S425G Glucocorticoid receptor DNA binding domain - (+)GRE complex Deposited 2015-07-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric
Chain W 391–480（90 aa）
Chain X 391–480（90 aa）
Mutation：S425G Mutation：S425G ZN ZINC ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；0.1 M HEPES, 20% PEG 8000, and 4% ethylene glycol
Resolution 2.30 Å R-free 0.279
5E69 Glucocorticoid receptor DNA binding domain - IL8 NF-kB response element complex Deposited 2015-10-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric
Chain A 391–480（90 aa） Fragment：unp residues 391-480
Chain B 391–480（90 aa） Fragment：unp residues 391-480
Not recorded ZN ZINC ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；0.1 M HEPES pH 7.5, 7.5% glycerol, 22% PEG 20000
Resolution 1.85 Å R-free 0.242
5E6A Glucocorticoid receptor DNA binding domain - PLAU NF-kB response element complex Deposited 2015-10-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric
Chain A 391–480（90 aa） Fragment：unp residues 391-480
Chain B 391–480（90 aa） Fragment：unp residues 391-480
Not recorded ZN ZINC ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；0.05 M sodium cacodylate, 0.05 M spermine, and 16% PEG 400
Resolution 2.20 Å R-free 0.266
5E6B Glucocorticoid receptor DNA binding domain - RELB NF-kB response element complex Deposited 2015-10-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric
Chain A 391–480（90 aa） Fragment：unp residues 391-480
Chain B 391–480（90 aa） Fragment：unp residues 391-480
Not recorded ZN ZINC ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；0.1 M HEPES pH 7.5, 7 uM spermine, 15% PEG 8000
Resolution 2.25 Å R-free 0.227
5E6C Glucocorticoid receptor DNA binding domain - CCL2 NF-kB response element complex Deposited 2015-10-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric
Chain A 391–480（90 aa） Fragment：unp residues 391-480
Chain B 391–480（90 aa） Fragment：unp residues 391-480
Not recorded ZN ZINC ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；0.1 M sodium malonate, 6% glycerol, 5% PEG 3350
Resolution 2.20 Å R-free 0.271
5E6D Glucocorticoid receptor DNA binding domain - ICAM1 NF-kB response element complex Deposited 2015-10-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric
Chain A 391–480（90 aa）
Chain B 391–480（90 aa）
Not recorded ZN ZINC ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；0.1 M HEPES pH 7.7, 3% ethylene glycol, 10% PEG 8000
Resolution 2.40 Å R-free 0.283
5EMC Transcription factor GRDBD and smGRE complex Deposited 2015-11-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric
Chain A 411–500（90 aa） Fragment：UNP RESIDUES 411-500
Chain B 411–500（90 aa） Fragment：UNP RESIDUES 411-500
Not recorded ZN ZINC ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；289 K；50mM HEPES, 100mM KCl, 10mM MgCl2, 5% PEG 400
Resolution 2.30 Å R-free 0.261
5EMP Transcription factor GRDBD and mmGRE complex Deposited 2015-11-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric
Chain A 411–500（90 aa） Fragment：UNP RESIDUES 411-500
Chain B 411–500（90 aa） Fragment：UNP RESIDUES 411-500
Not recorded ZN ZINC ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；289 K；50mM Tris, 200mM KCl, 50mM MgCl2, 10% PEG 4000
Resolution 2.30 Å R-free 0.238
5EMQ Transcription factor GRDBD and GRE complex Deposited 2015-11-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric
Chain A 411–500（90 aa） Fragment：UNP RESIDUES 411-500
Chain B 411–500（90 aa） Fragment：UNP RESIDUES 411-500
Not recorded ZN ZINC ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；289 K；50mM Na Cacodylate, 2.25mM Spermine, 18mM MgCl2, 9% isopropanol
Resolution 2.30 Å R-free 0.224
5G3J Discovery of New Selective Glucocorticoid Receptor Agonist Leads Deposited 2016-04-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 500–777（278 aa） Fragment：LIGAND BINDING DOMAIN, RESIDUES 500-777
Mutation：YES CPS 3-[(3-CHOLAMIDOPROPYL)DIMETHYLAMMONIO]-1-PROPANESULFONATE × 1 EDO 1,2-ETHANEDIOL × 1 E7T 5-[[(1S,2R,4R)-4-ethyl-6,7-bis(fluoranyl)-2,5-bis(oxidanyl)-2-(trifluoromethyl)-3,4-dihydro-1H-naphthalen-1-yl]amino]-1H-quinolin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；8% PEG8000, 15% ETHYLENE GLYCOL AND 0.1 M HEPES PH 7.5
Resolution 2.40 Å R-free 0.235
5G5W Structure guided design and discovery of Indazole ethers as highly potent, non-steroidal Glucocorticoid receptor modulators Deposited 2016-06-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 500–777（278 aa） Fragment：LIGAND BINDING DOMAIN, UNP RESIDUES 500-777
Mutation：YES EDO 1,2-ETHANEDIOL × 1 R8C 2,2,2-trifluoro-N-[(1R,2S)-1-{[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy}-1-phenylpropan-2-yl]acetamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；12% PEG8000, 20% ETHYLENE GLYCOL AND 0.1 M HEPES PH 7.5
Resolution 2.20 Å R-free 0.210
5NFP Glucocorticoid Receptor in complex with budesonide Deposited 2017-03-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 500–777（278 aa）
Not recorded CPS 3-[(3-CHOLAMIDOPROPYL)DIMETHYLAMMONIO]-1-PROPANESULFONATE × 1 EDO 1,2-ETHANEDIOL × 1 GOL GLYCEROL × 1 8W5 (1~{S},2~{S},4~{R},6~{R},8~{S},9~{S},11~{S},12~{S},13~{R})-9,13-dimethyl-11-oxidanyl-8-(2-oxidanylethanoyl)-6-propyl-5,7-dioxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosa-14,17-dien-16-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；2 ul of protein, 0.2ul of Polypropylene Glycol 400 and 0.8ul of well solution (10-12% PEG8000, 20% ethylene glycol and 0.1 M Hepes pH 7.5).
Resolution 2.10 Å R-free 0.202
5NFT Glucocorticoid Receptor in complex with AZD5423 Deposited 2017-03-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 500–777（278 aa）
Not recorded EDO 1,2-ETHANEDIOL × 3 8W8 2,2,2-tris(fluoranyl)-~{N}-[(1~{R},2~{S})-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-(3-methoxyphenyl)propan-2-yl]ethanamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；2 ul of protein and 1ul of well solution (8-12% PEG8000, 10-20% ethylene glycol and 0.1 M Hepes pH 7.5)
Resolution 2.30 Å R-free 0.215
5UC3 Structure of the dominant negative mutant Glucocorticoid Receptor alpha (L733K/N734P) complexed with RU-486 Deposited 2016-12-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 522–777（256 aa） Fragment：UNP residues 522-777
Chain B 522–777（256 aa） Fragment：UNP residues 522-777
Mutation：L733K, N734P Mutation：L733K, N734P 486 11-(4-DIMETHYLAMINO-PHENYL)-17-HYDROXY-13-METHYL-17-PROP-1-YNYL-1,2,6,7,8,11,12,13,14,15,16,17-DODEC AHYDRO-CYCLOPENTA[A]PHENANTHREN-3-ONE × 4 MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 6 EDO 1,2-ETHANEDIOL × 18 EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M HEPES, 0.1 M sodium citrate, 15 % MPD (v/v)
Resolution 2.01 Å R-free 0.212
5VA0 Glucocorticoid Receptor DNA Binding Domain in complex with AP-1 response element from VCAM-1 Promoter Deposited 2017-03-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric
Chain A 84–155（72 aa） Fragment：unp residues 84-155
Chain B 84–155（72 aa） Fragment：unp residues 84-155
Not recorded ZN ZINC ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；291 K；0.05 M Na Cacodylate (pH 7), 5 mM MgCl2, 1 mM Spermine, and 2 % t-Butanol
Resolution 2.29 Å R-free 0.231
5VA7 Glucocorticoid Receptor DNA Binding Domain - IL11 AP-1 recognition element Complex Deposited 2017-03-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric
Chain A 89–158（70 aa） Fragment：unp residues 89-158
Chain B 89–158（70 aa） Fragment：unp residues 89-158
Not recorded ZN ZINC ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；291 K；0.2 M Lithium Nitratie, 15 % PEG 3350, 1 % glycerol
Resolution 2.15 Å R-free 0.227
6BQU Human GR (418-507) in complex with monomeric DNA binding site Deposited 2017-11-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric
Chain A 421–490（70 aa）
Chain B 421–490（70 aa）
Not recorded ZN ZINC ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；0.005 M Magnesium sulfate heptahydrate, 0.05 M MES monohydrate, pH 6.0, 5 percent w/v, Polyethylene glycol 4,000
Resolution 2.50 Å R-free 0.249
6BSF Human GR (418-507) in complex with monomeric DNA binding site Deposited 2017-12-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric
Chain A 419–505（87 aa）
Chain B 419–505（87 aa）
Not recorded ZN ZINC ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；0.05 M MES monohydrate pH 6.0 0.005 M Magnesium sulfate heptahydrate 5% w/v Polyethylene glycol 4,000
Resolution 2.40 Å R-free 0.233
6CFN Crystal Structure of the DNA-free Glucocorticoid Receptor DNA Binding Domain Deposited 2018-02-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 418–506（89 aa）
Mutation：UNP Residues 418-506 ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；291 K；25% PEG3350, 50 mM Tris pH8.5, and 200 mM di-sodium tartrate
Resolution 2.50 Å R-free 0.248
6CFN Crystal Structure of the DNA-free Glucocorticoid Receptor DNA Binding Domain Deposited 2018-02-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 418–506（89 aa）
Mutation：UNP Residues 418-506 ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；291 K；25% PEG3350, 50 mM Tris pH8.5, and 200 mM di-sodium tartrate
Resolution 2.50 Å R-free 0.248
6CFN Crystal Structure of the DNA-free Glucocorticoid Receptor DNA Binding Domain Deposited 2018-02-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain C 418–506（89 aa）
Mutation：UNP Residues 418-506 ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；291 K；25% PEG3350, 50 mM Tris pH8.5, and 200 mM di-sodium tartrate
Resolution 2.50 Å R-free 0.248
6CFN Crystal Structure of the DNA-free Glucocorticoid Receptor DNA Binding Domain Deposited 2018-02-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain D 418–506（89 aa）
Mutation：UNP Residues 418-506 ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；291 K；25% PEG3350, 50 mM Tris pH8.5, and 200 mM di-sodium tartrate
Resolution 2.50 Å R-free 0.248
6CFN Crystal Structure of the DNA-free Glucocorticoid Receptor DNA Binding Domain Deposited 2018-02-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 5 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain E 418–506（89 aa）
Mutation：UNP Residues 418-506 ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；291 K；25% PEG3350, 50 mM Tris pH8.5, and 200 mM di-sodium tartrate
Resolution 2.50 Å R-free 0.248
6CFN Crystal Structure of the DNA-free Glucocorticoid Receptor DNA Binding Domain Deposited 2018-02-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 6 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain F 418–506（89 aa）
Mutation：UNP Residues 418-506 ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；291 K；25% PEG3350, 50 mM Tris pH8.5, and 200 mM di-sodium tartrate
Resolution 2.50 Å R-free 0.248
6CFN Crystal Structure of the DNA-free Glucocorticoid Receptor DNA Binding Domain Deposited 2018-02-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 7 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain G 418–506（89 aa）
Mutation：UNP Residues 418-506 ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；291 K；25% PEG3350, 50 mM Tris pH8.5, and 200 mM di-sodium tartrate
Resolution 2.50 Å R-free 0.248
6CFN Crystal Structure of the DNA-free Glucocorticoid Receptor DNA Binding Domain Deposited 2018-02-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 8 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain H 418–506（89 aa）
Mutation：UNP Residues 418-506 ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；291 K；25% PEG3350, 50 mM Tris pH8.5, and 200 mM di-sodium tartrate
Resolution 2.50 Å R-free 0.248
6DXK Glucocorticoid Receptor in complex with Compound 11 Deposited 2018-06-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 523–778（256 aa）
Chain B 523–778（256 aa）
Not recorded HJ4 (8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-17-(3,3-dimethylbut-1-yn-1-yl)-17-hydroxy-13-methyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one (non-preferred name) × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；293 K；pH 6.75
Resolution 3.05 Å R-free 0.260
6EL6 Glucocorticoid Receptor in complex with compound 4 Deposited 2017-09-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 500–777（278 aa）
Not recorded EDO 1,2-ETHANEDIOL × 1 B9Q ~{N}-[(1~{R},2~{S})-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-(6-methoxypyridin-3-yl)propan-2-yl]cyclopropanecarboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；8-10% PEG8000, 10-19% Ethylene Glycol, 0.1 M HEPES pH 7.5
Resolution 2.40 Å R-free 0.283
6EL7 Glucocorticoid Receptor in complex with compound 31 Deposited 2017-09-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 500–777（278 aa）
Not recorded EDO 1,2-ETHANEDIOL × 1 B9T ~{N}-[(1~{R},2~{S})-1-(2-bromanyl-4-cyano-phenoxy)-1-(2-cyclopropylpyrimidin-5-yl)propan-2-yl]-2,2-bis(fluoranyl)propanamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；8-10% PEG8000, 10-19% Ethylene Glycol, 0.1 M HEPES pH 7.5
Resolution 2.18 Å R-free 0.225
6EL9 Glucocorticoid Receptor in complex with AZD9567 Deposited 2017-09-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 500–777（278 aa）
Not recorded EDO 1,2-ETHANEDIOL × 1 B9W 2,2-bis(fluoranyl)-~{N}-[(1~{R},2~{S})-3-methyl-1-[1-(1-methyl-6-oxidanylidene-pyridin-3-yl)indazol-5-yl]oxy-1-phenyl-butan-2-yl]propanamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；8-10% PEG8000, 10-19% Ethylene Glycol, 0.1 M HEPES pH 7.5
Resolution 2.19 Å R-free 0.224
6X6D Glucocorticoid Receptor DNA binding domain in complex with unmodified precursor for a modern recognition element (pre-GBS) Deposited 2020-05-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric
Chain A 391–464（74 aa）
Chain B 391–464（74 aa）
Not recorded ZN ZINC ION × 4 CAC CACODYLATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；289.15 K；50 mM Sodium cacodylate pH 6.5, 80 mM Calcium chloride, 1 % glycerol, and 8.5% PEG 400
Resolution 2.48 Å R-free 0.211
6X6E Glucocorticoid Receptor DNA binding domain in complex with methylated precursor for a modern recognition element (methylated pre-GBS) Deposited 2020-05-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric
Chain A 391–465（75 aa）
Chain B 391–465（75 aa）
Not recorded ZN ZINC ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；298.15 K；50 mM sodium cacodylate pH 6.5, 80 mM calcium chloride, 1 % glycerol, and 7 % PEG 400
Resolution 2.00 Å R-free 0.212
6YMO Binary complex of 14-3-3 zeta with Glucocorticoid Receptor (GR) pS617 peptide Deposited 2020-04-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 611–623（13 aa）
Chain D 611–623（13 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) SAL 2-HYDROXYBENZOIC ACID × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 6.8；277.15 K；2.04 M ammonium sulfate, 0.2 M sodium citrate supplemented with 10% of an additive buffer containing 0.33% w/v 3-aminobenzoic acid, 0.33% w/v 3-aminosalicylic acid, 0.33% w/v salicylic acid and 0.02 M HEPES sodium pH 6.8
Resolution 2.02 Å R-free 0.234
6YO8 Binary complex of 14-3-3 zeta with Glucocorticoid Receptor (GR) pT524 peptide Deposited 2020-04-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain E 518–530（13 aa）
Chain F 518–530（13 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 8.3；277.15 K；1.29 M MgCl2, 22.5% PEG 3350, 0.1 M Tris pH 8.3, supplemented with 10% of an additive buffer containing 40% v/v of 2,5-Hexanediol
Resolution 2.09 Å R-free 0.238
6YO8 Binary complex of 14-3-3 zeta with Glucocorticoid Receptor (GR) pT524 peptide Deposited 2020-04-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain G 518–530（13 aa）
Chain H 518–530（13 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 8.3；277.15 K；1.29 M MgCl2, 22.5% PEG 3350, 0.1 M Tris pH 8.3, supplemented with 10% of an additive buffer containing 40% v/v of 2,5-Hexanediol
Resolution 2.09 Å R-free 0.238
6YOS Binary complex of 14-3-3 zeta with Glucocorticoid Receptor (GR) pT524 pS617 peptide Deposited 2020-04-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric
Chain C 518–530（13 aa）
Chain C 611–623（13 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 6.8；293.15 K；0.35 M MgCl2, 24.4% PEG 3350, 0. 1 M Bis Tris pH 5.5 supplemented with 10% of an additive buffer containing 0.06 M CHAPS, 0.06 M HEPES, 0.06 M Tris, 0.25% w/v Hexamminecobalt(III) chloride and 0.02 M HEPES sodium pH 6.8.
Resolution 2.75 Å R-free 0.261
7KRJ The GR-Maturation Complex: Glucocorticoid Receptor in complex with Hsp90 and co-chaperone p23 Deposited 2020-11-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain D 520–777（258 aa）
Mutation：F602S ATP ADENOSINE-5'-TRIPHOSPHATE × 2 MG MAGNESIUM ION × 2 DEX DEXAMETHASONE × 1 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.56 Å
7KW7 Atomic cryoEM structure of Hsp90-Hsp70-Hop-GR Deposited 2020-11-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain F 1–777（777 aa）
Mutation：F602S ADP ADENOSINE-5'-DIPHOSPHATE × 2 MG MAGNESIUM ION × 2 K POTASSIUM ION × 2 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions Cryogen ETHANE-PROPANE
Resolution 3.57 Å
7PRW The glucocorticoid receptor in complex with velsecorat, a PGC1a coactivator fragment and sgk 23bp Deposited 2021-09-22 Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein–DNA Heteromer；Protein × 3 PDB declaration: pentameric
Chain A 385–777（393 aa）
Chain B 385–777（393 aa）
Mutation：S404A, N517D, V571M, F602S, C638D Mutation：S404A, N517D, V571M, F602S, C638D ZN ZINC ION × 4 EDO 1,2-ETHANEDIOL × 6 82H Velsecorat × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；8.6 % PEG3350, 0.3 M 1,6-hexanediol, 0.1 M guanidine hydrochloride, 2 % 2,2,2-trifluoroethanol, 0.1 M BIS-TRIS propane pH 6.5
Resolution 2.50 Å R-free 0.263
7PRX wildtype ligand binding domain of the glucocorticoid receptor complexed with velsecorat and a PGC1a coactivator fragment Deposited 2021-09-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 529–777（249 aa）
Not recorded 82H Velsecorat × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；18 % PEG8000, 2 % 2-Propanol, 0.1 M Sodium acetate, 0.1 M HEPES pH 7.5
Resolution 2.20 Å R-free 0.281
8A9G Binary complex of 14-3-3 zeta Glucocorticoid Receptor (GR) pT524 peptide stabilised by (R)-para chloropyrrolidone1 Deposited 2022-06-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 518–530（13 aa）
Chain D 518–530（13 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) BTB 2-[BIS-(2-HYDROXY-ETHYL)-AMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 2 QJK 5-[(2~{R})-3-(4-chlorophenyl)carbonyl-2-(4-nitrophenyl)-4-oxidanyl-5-oxidanylidene-2~{H}-pyrrol-1-yl]-2-oxidanyl-benzoic acid × 2 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；277.15 K；0.4 M MgCl2 27% w/v PEG 3350 0.1 M Bis Tris 6.5 pH
Resolution 1.96 Å R-free 0.261
8FFV Cryo-EM structure of the GR-Hsp90-FKBP52 complex Deposited 2022-12-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 418–777（360 aa）
Mutation：F602S ATP ADENOSINE-5'-TRIPHOSPHATE × 2 MG MAGNESIUM ION × 2 DEX DEXAMETHASONE × 1 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.01 Å
8FFW Cryo-EM structure of the GR-Hsp90-FKBP51 complex Deposited 2022-12-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 418–777（360 aa）
Mutation：F602S ATP ADENOSINE-5'-TRIPHOSPHATE × 2 MG MAGNESIUM ION × 2 DEX DEXAMETHASONE × 1 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.23 Å
8VKZ Crystal structure of Glucocorticoid Receptor in complex with an inhibitor Deposited 2024-01-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain A 528–777（250 aa）
Chain B 528–777（250 aa）
Mutation：V571M, F602S, C638D Mutation：V571M, F602S, C638D A1ACE (4aR,4bS,5R,6aS,6bS,8R,9aR,10aR,10bR)-8-{4-[(3-aminophenyl)methyl]phenyl}-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H,8H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 5.5；296 K；24% (w/v) PEG 400, 200 mM ammonium acetate, 100 mM sodium citrate pH 5.5
Resolution 2.13 Å R-free 0.245

54 other PDB entries and 79 assemblies. Open the comparison page and filter oligomeric states

View Construct and Data Evidence
UniProt name GCR_HUMAN
Isoform —
PDB entities 1
Chains and sequence ranges Author chain A； PDBConstruct 1–393； UniProt 385–777 Author chain B； PDBConstruct 1–393； UniProt 385–777

Peroxisome proliferator-activated receptor gamma coactivator 1-alpha

OrganismNot specified

UniProt Q9UBK2

State in the Current Structure

Assembly Oligomeric State Construct Mutations and Modifications Ligands, Ions and Associated Components Method and Experimental Conditions Structure Quality
1 Protein–DNA Heteromer Protein × 3 DNA 2 PDB declaration: pentameric（5） Consistent with all polymer counts Chain F； UniProt 134–154 Not recorded Glucocorticoid receptor × 2 （P04150） ;DNA (5'-D(*TP*CP*GP*AP*CP*GP*GP*AP*CP*AP*AP*AP*AP*TP*GP*TP*TP*CP*TP*GP*TP*A)-3') ; × 1 ;DNA (5'-D(*TP*AP*CP*AP*GP*AP*AP*CP*AP*TP*TP*TP*TP*GP*TP*CP*CP*GP*TP*CP*GP*A)-3') ; × 1 ZN ZINC ION × 4 EDO 1,2-ETHANEDIOL × 3 GW6 (6alpha,11alpha,14beta,16alpha,17alpha)-6,9-difluoro-17-{[(fluoromethyl)sulfanyl]carbonyl}-11-hydroxy-16-methyl-3-oxoan drosta-1,4-dien-17-yl furan-2-carboxylate × 2 X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；8 % PEG3350, 0.3 M 1,6-hexanediol, 0.1 M guanidine hydrochloride, 8 % 2,2,2-trifluoroethanol, 0.1 M Bis Tris Propane pH 6.5 Resolution 2.70 Å R-free 0.253

Other States of the Same Protein in the Database

Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.

Other PDB Difference from Current Entry 7PRV Assembly / Oligomeric State Construct Mutations and Modifications Ligands, Ions and Non-polymers Method and Experimental Conditions Structure Quality
1XB7 X-ray structure of ERRalpha LBD in complex with a PGC-1alpha peptide at 2.5A resolution Deposited 2004-08-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain P 205–216（12 aa） Fragment：coactivator peptide (L3-site)
Mutation：C207A IOD IODIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；NaCl, KI, PEG4000, MES, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.50 Å R-free 0.247
3B1M Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator Cerco-A Deposited 2011-07-05 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 136–154（19 aa） Fragment：peptide containing LXXLL box, UNP residues 136-154
Not recorded KRC (9aS)-8-acetyl-N-[(2-ethylnaphthalen-1-yl)methyl]-1,7-dihydroxy-3-methoxy-9a-methyl-9-oxo-9,9a-dihydrodibenzo[b,d]furan-4-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；295 K；PEG 4000, sodium thiocyanate, Tris-hydrochloride, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 1.60 Å R-free 0.244
3CS8 Structural and Biochemical Basis for the Binding Selectivity of PPARg to PGC-1a Deposited 2008-04-09 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 141–152（12 aa）
Not recorded SO4 SULFATE ION × 4 BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.2；298 K；20% PEG3350, 0.2M Ammonium Iodide, pH 6.2, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.30 Å R-free 0.282
3D24 Crystal structure of ligand-binding domain of estrogen-related receptor alpha (ERRalpha) in complex with the peroxisome proliferators-activated receptor coactivator-1alpha box3 peptide (PGC-1alpha) Deposited 2008-05-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 198–219（22 aa） Fragment：Residues 198-219
Chain D 198–219（22 aa） Fragment：Residues 198-219
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；290 K；0.1 M Bis-Tris pH 5.5, 15% PEG 3350, 0.2 M Mg(NO3)2, VAPOR DIFFUSION, HANGING DROP, temperature 290K
Resolution 2.11 Å R-free 0.255
3D24 Crystal structure of ligand-binding domain of estrogen-related receptor alpha (ERRalpha) in complex with the peroxisome proliferators-activated receptor coactivator-1alpha box3 peptide (PGC-1alpha) Deposited 2008-05-07 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 198–219（22 aa） Fragment：Residues 198-219
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；290 K；0.1 M Bis-Tris pH 5.5, 15% PEG 3350, 0.2 M Mg(NO3)2, VAPOR DIFFUSION, HANGING DROP, temperature 290K
Resolution 2.11 Å R-free 0.255
3D24 Crystal structure of ligand-binding domain of estrogen-related receptor alpha (ERRalpha) in complex with the peroxisome proliferators-activated receptor coactivator-1alpha box3 peptide (PGC-1alpha) Deposited 2008-05-07 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 198–219（22 aa） Fragment：Residues 198-219
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；290 K；0.1 M Bis-Tris pH 5.5, 15% PEG 3350, 0.2 M Mg(NO3)2, VAPOR DIFFUSION, HANGING DROP, temperature 290K
Resolution 2.11 Å R-free 0.255
3U9Q Ligand binding domain of PPARgamma complexed with Decanoic Acid and PGC-1a peptide Deposited 2011-10-19 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 142–150（9 aa） Fragment：Peptide, UNP residues 142-150
Not recorded DKA DECANOIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 6.2；298 K；0.2 M sodium acetate (pH 6.2), 20% PEG 3350, 15% glycerol and 1 mM concentration of the ligand., VAPOR DIFFUSION, temperature 298K
Resolution 1.52 Å R-free 0.222
3V9T Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator Deposited 2011-12-28 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 136–154（19 aa）
Not recorded 17L (9aS)-8-acetyl-N-[(3-ethoxynaphthalen-1-yl)methyl]-1,7-dihydroxy-3-methoxy-9a-methyl-9-oxo-9,9a-dihydrodibenzo[b,d]furan-4-carboxamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；295 K；PEG 4000, sodium thiocyanate, Tris-hydrochloride, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 1.65 Å R-free 0.219
3V9V Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator Deposited 2011-12-28 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 136–154（19 aa）
Not recorded 21L methyl 3-{4-[({[(9aS)-8-acetyl-1,7-dihydroxy-3-methoxy-9a-methyl-9-oxo-9,9a-dihydrodibenzo[b,d]furan-4-yl]carbonyl}amino)methyl]naphthalen-2-yl}propanoate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；295 K；PEG 4000, sodium thiocyanate, Tris-hydrochloride, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 1.60 Å R-free 0.244
4QJR Crystal structure of human nuclear receptor sf-1 (nr5a1) bound to its hormone pip3 at 2.4 a resolution Deposited 2014-06-04 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 139–152（14 aa） Fragment：UNP residues 139-152
Not recorded PIZ (2S)-3-{[(R)-{[(1S,2S,3R,4S,5S,6S)-2,6-dihydroxy-3,4,5-tris(phosphonooxy)cyclohexyl]oxy}(hydroxy)phosphoryl]oxy}propane -1,2-diyl dihexadecanoate × 1 ACT ACETATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；10% PEG 8K, 0.025M MGOAC, 30% GLYCEROL, 0.067MM PIP3, 0.80MM 14MER EEPSLLKKLLLAPA, NANODROP, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 277K
Resolution 2.40 Å R-free 0.230
4QK4 Crystal structure of human nuclear receptor sf-1 (nr5a1) bound to pip2 at 2.8 a resolution Deposited 2014-06-05 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 139–152（14 aa） Fragment：UNP residues 139-152
Not recorded PIK (2S)-3-{[(R)-hydroxy{[(1R,2R,3S,4R,5R,6S)-2,3,6-trihydroxy-4,5-bis(phosphonooxy)cyclohexyl]oxy}phosphoryl]oxy}propane-1,2-diyl dihexadecanoate × 1 EDO 1,2-ETHANEDIOL × 5 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；SF-1, 6% PEG 8000, 0.2M MGOAC, 20% ETHYLENE GLYCOL, 0.067MM PIP2, 0.80MM 14-MER EEPSLLKKLLLAPA, NANODROP, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 277K
Resolution 2.81 Å R-free 0.241
5Z5S Crystal structure of the PPARgamma-LBD complexed with compound 13ab Deposited 2018-01-19 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 136–154（19 aa）
Not recorded RTE 3-{[6-(4-chloro-3-fluorophenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy}benzoic acid × 1 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；295 K；PEG 4000, NaSCN, Tris-HCl
Resolution 1.80 Å R-free 0.229
5Z6S Crystal structure of the PPARgamma-LBD complexed with compound DS-6930 Deposited 2018-01-25 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 136–154（19 aa）
Not recorded RTF 3-[[6-(3,5-dimethylpyridin-2-yl)oxy-1-methyl-benzimidazol-2-yl]methoxy]benzoic acid × 1 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；295 K；PEG 4000, sodium thiocyanate, Tris-hydrochloride
Resolution 1.80 Å R-free 0.226
6AD9 Crystal Structure of PPARgamma Ligand Binding Domain in complex with dibenzooxepine derivative compound-9 Deposited 2018-07-31 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 141–152（12 aa） Fragment：LXLL motif
Not recorded KK4 3-[(1E)-1-{8-[(4-methyl-2-propyl-1H-benzimidazol-1-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}ethyl]-1,2,4-oxadiazol-5(4H)-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 8.5；293 K；0.5M LiCl, 0.1M Tris-HCl pH 8.5, 28% PEG 6000
Resolution 2.20 Å R-free 0.240
6FZF PPAR mutant complex Deposited 2018-03-14 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 139–152（14 aa）
Not recorded EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；290 K；25% PEG 3350, 0.2 M ammonium sulfate, 0.1 M Bis-Tris pH 6.5
Resolution 1.95 Å R-free 0.194
6FZF PPAR mutant complex Deposited 2018-03-14 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 139–152（14 aa）
Not recorded EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；290 K；25% PEG 3350, 0.2 M ammonium sulfate, 0.1 M Bis-Tris pH 6.5
Resolution 1.95 Å R-free 0.194
6FZP PPAR gamma complex. Deposited 2018-03-15 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 139–152（14 aa）
Not recorded EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；290 K；NH4 acetate 0.3M, Hepes 0.1M pH 7.5, di-sodium tartrate 0.8 M
Resolution 2.30 Å R-free 0.252
6IZM Crystal structure of the PPARgamma-LBD complexed with compound 1l Deposited 2018-12-20 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 136–154（19 aa）
Not recorded B0X 3-[[6-(2,6-dimethylpyridin-3-yl)oxy-1-methyl-benzimidazol-2-yl]methoxy]benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；295 K；PEG 4000, NaSCN, Tris-HCl
Resolution 1.80 Å R-free 0.248
6IZN Crystal structure of the PPARgamma-LBD complexed with compound 3g Deposited 2018-12-20 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 136–154（19 aa）
Not recorded B1O 3-[[6-(2,6-dimethylpyridin-3-yl)oxy-7-fluoranyl-1-methyl-benzimidazol-2-yl]methoxy]benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；295 K；PEG 4000, NaSCN, Tris-HCl
Resolution 1.75 Å R-free 0.265
6LN4 Estrogen-related receptor beta(ERR2) in complex with PGC1a-2a Deposited 2019-12-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 207–216（10 aa）
Mutation：C207A No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；100mM Kcl, 20% PEG 4000
Resolution 2.61 Å R-free 0.245
6LN4 Estrogen-related receptor beta(ERR2) in complex with PGC1a-2a Deposited 2019-12-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 207–216（10 aa）
Mutation：C207A No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；100mM Kcl, 20% PEG 4000
Resolution 2.61 Å R-free 0.245
6NWK Structure of the Ancestral Glucocorticoid Receptor 2 ligand binding domain in complex with dexamethasone and PGC1a coregulator fragment Deposited 2019-02-06 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 141–152（12 aa） Fragment：UNP Residues 141-152
Not recorded DEX DEXAMETHASONE × 1 FMT FORMIC ACID × 1 ACE ACETYL GROUP × 1 DMS DIMETHYL SULFOXIDE × 2 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；289.15 K；0.3 M sodium chloride, 2.6 M sodium formate and 0.1 M PIPES pH 7.0
Resolution 1.65 Å R-free 0.212
6NWL Structure of the Ancestral Glucocorticoid Receptor 2 ligand binding domain in complex with hydrocortisone and PGC1a coregulator fragment Deposited 2019-02-06 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 141–152（12 aa） Fragment：UNP Residues 141-152
Not recorded HCY (11alpha,14beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione × 1 GOL GLYCEROL × 3 TLA L(+)-TARTARIC ACID × 1 EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 1 SCN THIOCYANATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；289.15 K；0.05 M sodium thiocyanate, 0.95 M sodium tartrate dibasic dehydrate and 0.1M HEPES pH 7.5
Resolution 1.59 Å R-free 0.193
6T1V Structure of PPARg H494Y mutant in complex with GW1929 Deposited 2019-10-06 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 139–152（14 aa）
Not recorded EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；290 K；0.2 M ammonium acetate, 0.1 M Hepes pH 7.5, trisodium citrate 1.2M
Resolution 2.21 Å R-free 0.196
6W9K Structure of the Ancestral Glucocorticoid Receptor 2 ligand binding domain in complex with Prednisolone and PGC1a coregulator fragment Deposited 2020-03-23 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 142–151（10 aa） Fragment：amino acids 142-151
Not recorded TUA prednisolone × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；289.15 K；0.2 M ammonium acetate, 3.0 M sodium formate, and 0.1 M HEPES 8.0
Resolution 1.60 Å R-free 0.192
6W9L Structure of the Ancestral Glucocorticoid Receptor 2 ligand binding domain in complex with deacetylated deflazacort and PGC1a coregulator fragment Deposited 2020-03-23 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 141–152（12 aa） Fragment：amino acids 141-152
Not recorded TUS (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8-trimethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]oxazol-2-one × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；289.15 K；0.2 M ammonium acetate, 2.5 M sodium formate, and 0.1 M Tris pH 8.5
Resolution 1.45 Å R-free 0.200
7E2E Crystal structure of the Estrogen-Related Receptor alpha (ERRalpha) ligand-binding domain (LBD) in complex with an agonist DS45500853 and a PGC-1alpha peptide Deposited 2021-02-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain P 205–216（12 aa）
Chain Q 205–216（12 aa）
Mutation：C207A Mutation：C207A HVO 1-[4-(3-tert-butyl-4-oxidanyl-phenoxy)phenyl]ethanone × 2 IOD IODIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.6；295 K；18% (v/v) PEG 3350, 0.2 M NaI, 0.1 M HEPES (pH 7.6)
Resolution 2.70 Å R-free 0.305
7KHT The acyl chains of phosphoinositide PIP3 alter the structure and function of nuclear receptor Steroidogenic Factor-1 (SF-1) Deposited 2020-10-22 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 139–152（14 aa）
Not recorded WES (2S)-3-{[(S)-{[(1S,2S,3R,4S,5S,6S)-2,6-dihydroxy-3,4,5-tris(phosphonooxy)cyclohexyl]oxy}(hydroxy)phosphoryl]oxy}propane-1,2-diyl (9E,9'E)di-octadec-9-enoate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；20% PEG 3350 and 0.2 M magnesium formate
Resolution 2.50 Å R-free 0.249
7PRW The glucocorticoid receptor in complex with velsecorat, a PGC1a coactivator fragment and sgk 23bp Deposited 2021-09-22 Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein–DNA Heteromer；Protein × 3 PDB declaration: pentameric
Chain F 134–154（21 aa）
Not recorded ZN ZINC ION × 4 EDO 1,2-ETHANEDIOL × 6 82H Velsecorat × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；8.6 % PEG3350, 0.3 M 1,6-hexanediol, 0.1 M guanidine hydrochloride, 2 % 2,2,2-trifluoroethanol, 0.1 M BIS-TRIS propane pH 6.5
Resolution 2.50 Å R-free 0.263
7PRX wildtype ligand binding domain of the glucocorticoid receptor complexed with velsecorat and a PGC1a coactivator fragment Deposited 2021-09-22 Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 134–154（21 aa）
Not recorded 82H Velsecorat × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；18 % PEG8000, 2 % 2-Propanol, 0.1 M Sodium acetate, 0.1 M HEPES pH 7.5
Resolution 2.20 Å R-free 0.281
8BF1 High-resolution structure of unliganded PPAR gamma in complex with the peptide PGC-1 alpha Deposited 2022-10-23 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 136–154（19 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；292.15 K；0.1 M Bis-Tris pH 6.5 0.2 M ammonium acetate 0.01 M gunidine hydrochloride
Resolution 1.36 Å R-free 0.181
8DK4 Peroxisome proliferator-activated receptor gamma in complex with VSP-51-2 Deposited 2022-07-02 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 138–152（15 aa） Fragment：UNP residues 138-152
Not recorded SJ9 5-(benzylcarbamoyl)-1-[(4-chloro-3-fluorophenyl)methyl]-1H-indole-2-carboxylic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M of trisodium citrate, pH 5.5, 20% w/v PEG3350
Resolution 2.60 Å R-free 0.255
8YT6 Human PPAR alpha ligand binding domain in complex with a 1H-pyrazolo[3,4-b]pyridine-derived compound Deposited 2024-03-25 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 135–156（22 aa）
Not recorded A1LZX 6-(2-ethoxyethyl)-1-(4-fluorophenyl)-3-pentan-3-yl-pyrazolo[3,4-b]pyridine-4-carboxylic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；100 mM HEPES-NaOH, 19-23% PEG 4000, 19-23% 1,2-propanediol
Resolution 1.85 Å R-free 0.265
8YT9 Human PPAR alpha ligand binding domain in complex with a 1H-pyrazolo[3,4-b]pyridine-derived compound Deposited 2024-03-25 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 135–156（22 aa）
Not recorded A1LZY 1-(4-fluorophenyl)-6-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-3-pentan-3-yl-pyrazolo[3,4-b]pyridine-4-carboxylic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；100 mM HEPES-NaOH, 19-23% PEG 4000, 19-23% 1,2-propanediol
Resolution 1.59 Å R-free 0.206
8YTL Human PPAR alpha ligand binding domain in complex with a 1H-pyrazolo[3,4-b]pyridine-derived compound Deposited 2024-03-26 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 135–156（22 aa）
Not recorded PGO S-1,2-PROPANEDIOL × 1 A1LZ0 1-(4-fluorophenyl)-6-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]-3-pentan-3-yl-pyrazolo[3,4-b]pyridine-4-carboxylic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；100 mM HEPES-NaOH, 19-23% PEG 4000, 19-23% 1,2-propanediol
Resolution 2.00 Å R-free 0.260
8YU8 Human PPAR alpha ligand binding domain in complex with a 1H-pyrazolo[3,4-b]pyridine-derived compound Deposited 2024-03-27 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 135–156（22 aa）
Not recorded A1LZ1 6-(4-butoxycarbonylpiperazin-1-yl)-1-(4-fluorophenyl)-3-pentan-3-yl-pyrazolo[3,4-b]pyridine-4-carboxylic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；100 mM HEPES-NaOH, 19-23% PEG 4000, 19-23% 1,2-propanediol
Resolution 1.95 Å R-free 0.259
8YWU Human PPAR alpha ligand binding domain in complex with a 1H-pyrazolo[3,4-b]pyridine-derived compound Deposited 2024-04-01 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 135–156（22 aa）
Not recorded A1LZ9 1-(4-fluorophenyl)-6-[2-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]ethyl]-3-pentan-3-yl-pyrazolo[3,4-b]pyridine-4-carboxylic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；100 mM HEPES-NaOH, 19-23% PEG 4000, 19-23% 1,2-propanediol
Resolution 1.77 Å R-free 0.230
8YWV Human PPAR alpha ligand binding domain in complex with a 1H-pyrazolo[3,4-b]pyridine-derived compound Deposited 2024-04-01 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 135–156（22 aa）
Not recorded A1L0A 1-(4-fluorophenyl)-6-[4-(2-methylpropoxycarbonyl)piperazin-1-yl]-3-pentan-3-yl-pyrazolo[3,4-b]pyridine-4-carboxylic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；100 mM HEPES-NaOH, 19-23% PEG 4000, 19-23% 1,2-propanediol
Resolution 2.01 Å R-free 0.251
9F7W Human PPARgamma ligand binding domain in complex with co-activator 1alpha peptide and bisphenol A (BPA) Deposited 2024-05-05 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 136–154（19 aa）
Not recorded 2OH 4,4'-PROPANE-2,2-DIYLDIPHENOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；292.15 K；20% w/v PEG 3350, 0.2 M magnesium acetate, 137 mM sodium chloride, 8.1 mM disodium hydrogen phosphate, 1.5 mM potassium dihydrogen phosphate, 2.7 mM potassium chloride, 1 mM peptide, 15 mM BPB, 1.5 % DMSO
Resolution 1.25 Å R-free 0.189
9F7X Human PPARgamma ligand binding domain in complex with co-activator 1alpha peptide and bisphenol B (BPB) Deposited 2024-05-05 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 136–154（19 aa）
Not recorded H3W bisphenol-B × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；292.15 K；20% w/v PEG 3350, 0.337 M sodium chloride, 8.1 mM disodium hydrogen phosphate, 1.5 mM potassium dihydrogen phosphate, 2.7 mM potassium chloride, 1 mM peptide, 15 mM BPB, 1.5 % DMSO
Resolution 1.63 Å R-free 0.290
9IWN X-ray structure of human PPARalpha ligand binding domain-intrinsic fatty acid (E. coli origin)-PGC1alpha coactivator peptide co-crystals obtained by cross-seeding Deposited 2024-07-25 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 137–151（15 aa）
Not recorded PLM PALMITIC ACID × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；277 K；0.1M HEPES (pH 7.0), 25% PEG 3350
Resolution 1.59 Å R-free 0.208
9IWO X-ray structure of human PPARalpha ligand binding domain-GW7647-PGC1alpha coactivator peptide co-crystals obtained by cross-seeding Deposited 2024-07-25 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 137–151（15 aa）
Not recorded 2VN 2-[(4-{2-[(4-cyclohexylbutyl)(cyclohexylcarbamoyl)amino]ethyl}phenyl)sulfanyl]-2-methylpropanoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；277 K；0.1M HEPES (pH 7.0), 25% PEG 3350
Resolution 1.49 Å R-free 0.213
9T5S Crystal structure of human PPARalpha in complex with co-activator PGC-1 alpha peptide and bempedoic acid Deposited 2025-11-05 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 136–154（19 aa）
Not recorded A1JTY Bempedoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；292.15 K；20 %w/v PEG 3350, 0.2 M Na2HPO4
Resolution 1.74 Å R-free 0.211
9T5S Crystal structure of human PPARalpha in complex with co-activator PGC-1 alpha peptide and bempedoic acid Deposited 2025-11-05 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 136–154（19 aa）
Not recorded A1JTY Bempedoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；292.15 K；20 %w/v PEG 3350, 0.2 M Na2HPO4
Resolution 1.74 Å R-free 0.211

39 other PDB entries and 44 assemblies. Open the comparison page and filter oligomeric states

View Construct and Data Evidence
UniProt name PRGC1_HUMAN
Isoform —
PDB entities 4
Chains and sequence ranges Author chain F； PDBConstruct 1–21； UniProt 134–154

The page prioritizes protein identity, the current assembly, associated components, oligomeric state and cross-PDB links. Chain mapping and sequence ranges are retained as data evidence. Internal IDs, import timestamps and assembly operation expressions are maintenance fields and are not shown here.

SAXS scattering curve SAXS Profile

SAXS profile for 7prv

P(r) Distance Distribution P(r) Distribution

P(r) distribution for 7prv
Download Download
▼

2. Structure Basics 2. Structure Basics

Entry ID entry_id7prv
Deposition date deposition_date2021-09-22
Structure title titleThe glucocorticoid receptor in complex with fluticasone furoate, a PGC1a coactivator fragment and sgk 23bp
Keywords keywordsnuclear receptor, ligand-activated transcription factor, multi-domain, complex, agonist, SIGNALING PROTEIN; SIGNALING PROTEIN
Experimental Method methodX-RAY DIFFRACTION
▼

3. SAXS Parameters (CRYSOL theoretical calculation) 3. SAXS Parameters (CRYSOL)

Radius of gyration Rg (Guinier) rg_guinier30.86 Å
Radius of gyration Rg (electron density) rg_electron29.57 Å
Forward intensity I(0) i0152861000.00
Molecular weight molecular_weight90344.0 kDa
Excluded volume excluded_volume109690 ų
Envelope volume envelope_volume140740 ų
Hydration-shell volume shell_volume39142 ų
Envelope diameter envelope_diameter97.1 Å
Shell Rg shell_rg37.20 Å
Envelope Rg envelope_rg29.54 Å
Shape Rg shape_rg29.54 Å
Total Rg total_rg30.30 Å
Total atoms total_atoms6248
Residues n_residues698
Spherical-harmonic order n_harmonics20
q range q_range— – 0.5000 Å−1
Data points n_points101
Shell type shell_typedirectional
Solvent electron density solvent_density0.3340 e/ų
Shell contrast contrast_shell0.0300 e/ų
CRYSOL version crysol_version4.1.3
▼

4. P(r) Distance Distribution (GNOM inversion) 4. P(r) Analysis (GNOM)

Maximum dimension Dmax dmax94.2 Å
Rg (real space) rg_real30.70 Å
Rg uncertainty (real space) rg_real_error0.65 Å
I(0) (real space) i0_real1.5290e+08
I(0) uncertainty (real space) i0_real_error2.3820e+06
Rg (reciprocal space) rg_reciprocal30.77 Å
I(0) (reciprocal space) i0_reciprocal152900000.0000
Solution quality estimate total_estimate0.9129
Solution quality rating solution_quality EXCELLENT a EXCELLENT solution
P(r) peaks n_peaks1
Primary peak position r_peak_primary40.6 Å
Skewness Skewness skewness0.088
Kurtosis Kurtosis kurtosis-0.627
Angular range angular_range— – 0.2550 Å−1
Current regularization parameter α current_alpha0.0000
Highest regularization parameter α highest_alpha17950000.0000
Real-space data points n_real_points52
GNOM version gnom_version4.1.3
Quality Criteria quality_criteria AN1: 0.000; Oscil: 0.967; Stabil: 1.000; Sysdev: 1.000; Positv: 1.000; Valcen: 0.999; Smooth: 0.963
▶

5. Crystallography and Experiment 5. Crystallography & Experiment

▶

6. Entities and Polymers Entities & Polymers (8)

▶

8. Citations (1)

▶

9. Files and Curves (10)